1Parnetti L, Mecocci P, Gaiti A, et al. Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type [J]. Eur J Drug Metab Pharmacokinet, 1990, 15(1): 75-78.
2Ponzio F, Pozzi O, Banfi S, et al. Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam. Oxiracetam: brain entry and pharmacological effects [J]. Pharmacopsychiatry, 1989, 22(Suppl 2): 111-115.
3Banfi S, Dorigotti L, Abbracchio MP, et al. Methylazoxymethanol microencephaly in rats: neurochemical characterization and behavioral studies with the nootropic oxiracetam [J]. Pharmacol Res Commun, 1984, 16(1): 67-83.
5Lecaillon JB, Dubois JP, Coppens H, et al. Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects [J]. Eur J Drug Metab Pharmacokinet, 1990, 15(3): 223-230.
6Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms [J]. Prog Neuropsychopharmacol Biol Psychiatry, 1989, 13(Suppl): S77-88.
7Spignoli G, Pepeu G. Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia [J]. Eur J Pharmacol, 1986, 126(3): 253-257.
8Spignoli G, Pepeu G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine [J]. Pharmacol Biochem Behav, 1987, 27(3): 491-495.
9Spignoli G, Pedata F, Giovannelli L, et al. Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition [J]. Clin Neuropharmacol, 1986, 9(Suppl 3): S39-47.
10Mochizuki D, Sugiyama S, Shinoda Y. Biochemical studies of oxiracetam (CT-848) on cholinergic neurons [J]. Nippon Yakurigaku Zasshi, 1992, 99(1): 27-35.
